BioSpace News Archive

Enrollment Continues in Phase 3 RALLY Study, with Interim Analysis of the First 50 Percent of Participants Expected Third Quarter 2021 Topline Results of Approximately 670 Participants in RALLY Expected Fourth Quarter 2021 Positive Topline Results from RELIEF, the First Phase 3 Study of TNX-102 SL for Management of Fibromyalgia, Previously Announced December 2020

IGM Biosciences, Inc. (IGM), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the appointment of Lisa L. Decker, Ph.D., to the newly created position of Chief Business Officer. Ms. Decker joins IGM with twenty years of experience in business development strategy, transactions and alliance management.

New Findings from Ongoing Collaborations with University of Alabama at Birmingham and Saint Louis University Studies Show Complete Protection Against Lethal Challenge and Dramatic Reduction in Viral Replication Systemic and Mucosal Antibody Responses Durable for at Least 6 Months

Company had $120.9 million of cash and cash equivalents as of March 12, 2021 Substantial increase in liquidity driven by equity investment from Suvretta Capital and sale of Arvelle shares Company estimates it is fully funded through major upcoming milestones for GM1 gene therapy program

The Center for Cancer and Blood Disorders, a comprehensive cancer center serving 12,000 patients annually in North Texas, announced the practice will offer cancer patients and their caregivers COVID-19 vaccinations beginning tomorrow.

Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its President and Chief Executive Officer, Peter L. Hoang , will present at

Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announces extensive progress in five studies focused on the performance of DehydraTECHTM CBD as a treatment for hypertension.

Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that an independent Data Safety Monitoring Board (DSMB) has completed its interim review of the company’s Phase 2b GALACTIC-1 study of GB0139 for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

Total of $195 million raised to date to support expansion and clinical advancement of Graphite Bio pipeline of targeted gene integration therapies with curative potential The financing, led by RA Capital Management and Rock Springs Capital, included participation by other prominent new and existing investors

9 Meters Biopharma (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced that it will host a key opinion leader (KOL) webinar on short bowel syndrome (SBS) and provide an update on the NM-002 (proprietary GLP-1 agonist) development program on Tuesday, March 23, 2021 at 11am Eastern Time.